Portfolio company
Labrys Biologics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops monoclonal antibody therapeutics for the preventive treatment of chronic and episodic migraines in patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
CoLucid
This biopharmaceutical company develops oral therapies for the acute treatment of migraine headaches in adult patients.
Aiolos Bio
This biopharmaceutical company develops monoclonal antibody therapies for patients suffering from respiratory and inflammatory conditions such as moderate-to-severe asthma.
Biohaven
This biopharmaceutical company develops therapeutics for patients with debilitating neurological, neuroinflammatory, and metabolic diseases, as well as immunological and oncology disorders.
Arxx Therapeutics
This biotechnology firm develops monoclonal antibody therapies for patients suffering from chronic inflammatory and fibrotic diseases.
Miist Therapeutics
This company develops inhaled drug delivery devices providing rapid symptom relief for patients suffering from migraines or seeking smoking cessation.
Brise Pharmaceuticals Co., LTD.
This biopharmaceutical company develops analgesic treatments for patients with severe pain conditions including migraine, neuropathic pain, and musculoskeletal pain.
Latigo Biotherapeutics
This clinical-stage biopharmaceutical company develops non-opioid medicines to treat patients suffering from pain without the risk of addiction.
Laigo Bio
This company develops bispecific antibody therapies that remove disease-causing membrane proteins to treat patients with cancer and autoimmune disorders.
